Get the Stockscreener App
7.945
0.94%
-0.075
After Hours:
7.95
0.005
+0.06%
Verrica Pharmaceuticals Inc stock is traded at $7.945, with a volume of 156.16K.
It is down -0.94% in the last 24 hours and down -3.93% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$8.02
Open:
$8.13
24h Volume:
156.16K
Relative Volume:
0.53
Market Cap:
$127.04M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-5.4048
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-4.28%
1M Performance:
-3.93%
6M Performance:
-2.99%
1Y Performance:
+13.55%
1-Day Range:
$7.83
$8.15
1-Week Range:
$7.83
$8.95
52-Week Range:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
7.945 | 128.24M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion - MyChesCo
Why Verrica Pharmaceuticals Inc. stock is favored by top institutionsJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Verrica Pharmaceuticals Inc. stock see insider buyingRate Hike & Daily Market Momentum Tracking - ulpravda.ru
Will Verrica Pharmaceuticals Inc. (1NE) stock outperform benchmarks2025 Major Catalysts & Accurate Trade Setup Notifications - ulpravda.ru
Verrica doses first patient in phase 3 trial for common wart treatment - Investing.com Nigeria
First Patient Dosed in Phase 3 VP-102 Common Warts Program - Dermatology Times
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating - Investing.com
Verrica Pharmaceuticals announces first patient dosed in phase 3 program - MarketScreener
Verrica Pharmaceuticals (VRCA) Begins Phase 3 Trials for Common Warts Treatment - GuruFocus
New wart treatment enters Phase 3 testing for 22M U.S. patients - Stock Titan
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Sahm
Verrica Pharmaceuticals adds Caligan Partner to board - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Decreases By 26.2% - MarketBeat
Verrica Pharmaceuticals appoints Charles Frantzreb to board and approves equity grants - Investing.com Canada
Verrica Pharmaceuticals appoints Charles Frantzreb to board and approves equity grants By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Adds Caligan Partner to Board - TipRanks
Verrica Pharmaceuticals Appoints New Director - TradingView — Track All Markets
Verrica Pharmaceuticals Inc. Appoints Charles Frantzreb as Director, Effective December 26, 2025 - MarketScreener
Can Verrica Pharmaceuticals Inc. stock reach $100 price targetHigh Yield Income Stocks & Low Cost Portfolio Tips - bollywoodhelpline.com
Verrica Pharmaceuticals (VRCA) Stock Price, Quote, News & History - Benzinga
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Gains Report: Can Verrica Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Reactions & Entry Point Confirmation Signals - Улправда
Is Verrica Pharmaceuticals Inc. stock a safe buy before earningsTrade Analysis Report & AI Optimized Trading Strategy Guides - Улправда
Will Verrica Pharmaceuticals Inc. stock pay special dividendsQuarterly Performance Summary & AI Powered Market Entry Strategies - Улправда
Can Verrica Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Outlook & Verified Swing Trading Watchlists - Улправда
Verrica Pharmaceuticals (FRA:1NE0) EV-to-OCF : -4.47 (As of Dec. 19, 2025) - GuruFocus
Can Verrica Pharmaceuticals Inc. stock weather global recessionJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Verrica Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Verrica Pharmaceuticals Inc. stock a buy on dipsJuly 2025 Highlights & AI Powered Trade Plan Recommendations - Улправда
Will Verrica Pharmaceuticals Inc. (1NE) stock boost dividends furtherMarket Sentiment Review & Reliable Entry Point Alerts - DonanımHaber
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Increased to Buy at Brookline Capital Management - Defense World
Brookline Capital upgrades Verrica Pharmaceuticals (VRCA) - MSN
Aug Drivers: Will Verrica Pharmaceuticals Inc. stock see insider buyingMarket Sentiment Review & Weekly Top Gainers Alerts - Улправда
Is Verrica Pharmaceuticals Inc. (1NE) stock undervalued after correction2025 Sector Review & Verified Momentum Stock Alerts - Улправда
Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Upgraded by Brookline Capital Management - MarketBeat
Verrica Pharmaceuticals (VRCA) Receives Upgrade from Brookline C - GuruFocus
Verrica Pharmaceuticals stock upgraded to Buy by Brookline on pipeline potential - Investing.com Nigeria
Top Premarket Decliners - marketscreener.com
[S-3] Verrica Pharmaceuticals Inc. Shelf Registration Statement | VRCA SEC FilingForm S-3 - Stock Titan
Verrica Pharmaceuticals Earnings Notes - Trefis
Armistice Capital LLC Increases Stock Holdings in Verrica Pharmaceuticals Inc. $VRCA - Defense World
Verrica’s $50 Million PIPE Deal Sparks Big Questions About Its Next Growth Phase - MSN
Verrica Pharmaceuticals Inc. announced that it has received $50.067383 million in funding from BKB Growth Investments, LLC and other investors. - marketscreener.com
How buybacks impact Verrica Pharmaceuticals Inc. stock value2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
How Verrica Pharmaceuticals Inc. (1NE) stock performs during market turbulenceJuly 2025 Action & Real-Time Sentiment Analysis - Newser
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verrica Pharmaceuticals Inc Stock (VRCA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kirby John J. | Interim CFO |
Nov 25 '25 |
Buy |
4.24 |
3,536 |
15,001 |
8,962 |
| Zawitz David | Chief Operating Officer |
Nov 25 '25 |
Buy |
4.24 |
10,000 |
42,425 |
21,000 |
| Rieger Jayson | CEO and President |
Nov 25 '25 |
Buy |
4.24 |
94,311 |
400,114 |
182,593 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
2,750,762 |
11,670,108 |
3,348,372 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
1,375,380 |
5,835,050 |
3,958,189 |
| Hayes Christopher G. | CHIEF LEGAL OFFICER |
Mar 17 '25 |
Sale |
0.65 |
4,315 |
2,805 |
176,458 |
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):